ClinicalTrials.gg
CompletedNCT01208181Updated Jun 18, 2024Results posted

A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

A Phase 3 interventional study of Etoricoxib 60 mg and Etoricoxib 90 mg in Arthritis, Rheumatoid, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,404
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 2-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study.

02

Conditions studied

  • Arthritis, Rheumatoid
03

In context

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

This study's enrollment of 1,404 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female ≥ 18 years of age in general good health (other than RA)
  • Has an American College of Rheumatology Rheumatoid Clinical Response Criteria (ACR) Functional Class I, II, or III
  • Has a diagnosis of RA at least 6 months ago and was at least 16 years of age when diagnosed
  • Has a history of positive therapeutic benefit with nonsteroidal anti-inflammatory drugs (NSAIDs) and is taking an NSAID on a regular basis and at a therapeutic dose level and is not anticipated to undergo a change during the study

Exclusion criteria

Exclusion Criteria:

  • Has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy
  • Has a history of gastric or biliary surgery (including gastric bypass surgery) or small intestine surgery that causes clinical malabsorption
  • Has an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease
  • Has a confirmed medical diagnosis of ischemic heart disease, cerebrovascular disease, or peripheral artery occlusive disease
  • Class II-IV congestive heart failure
  • Has uncontrolled hypertension (systolic >160 mm Hg or diastolic > 90 mm Hg) at Visit 1 or Visit 2
  • Has a clinical diagnosis of hepatic insufficiency defined as score ≥5
  • Has estimated ≤30 mL/min
  • Has a history of neoplastic disease within 5 years (exceptions: basal cell carcinoma or carcinoma in situ of the cervix)
  • Is allergic to etoricoxib; history of a significant clinical or laboratory adverse experience associated with etoricoxib; to aspirin or NSAIDs; or allergy to acetaminophen/paracetamol
  • Has a personal or family history of an inherited or acquired bleeding disorder
  • Requires oral therapy in excess of the equivalent of 10 mg daily of prednisone and/or have not been on a stable dose for at least 4 weeks prior to Visit 1 and/or whose dose is not expected to remain stable during the study
  • Treated with B-cell depleting therapies within the past 6 months or anticipate this treatment during this trial
  • Is a recreational or illicit drug use, or history within 5 years of drug or alcohol abuse/dependence;
  • Is morbidly obese (defined as ≥40 kg/m\^2)
  • Is pregnant or breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,404 participants (actual)

Study arms

  • Experimental
    Etoricoxib 60 mg/Etoricoxib 60 mg

    The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.

    Drug: Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 60 mg

  • Experimental
    Etoricoxib 60 mg/Etoricoxib 90 mg

    The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.

    Drug: Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 60 mg

  • Experimental
    Etoricoxib 90 mg

    The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.

    Drug: Etoricoxib 90 mg · Drug: Placebo to Etoricoxib 90 mg

  • Placebo comparator
    Placebo

    The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.

    Drug: Placebo to Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 90 mg

Interventions

  • One tablet orally once daily for 6 weeks.

    Also known as: MK-0663

  • One tablet orally once daily for 6 weeks.

    Also known as: MK-0663

  • DrugPlacebo to Etoricoxib 60 mg

    One tablet orally once daily for 6 weeks.

  • DrugPlacebo to Etoricoxib 90 mg

    One tablet orally once daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)

    Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.

    Time frame: Baseline and Week 6

  2. Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)

    A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.

    Time frame: Baseline and Week 6

  3. Percentage of Participants Who Experienced at Least One Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

    Time frame: Up to 112 days

  4. Percentage of Participants Who Discontinued Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

    Time frame: Up to Week 12

Secondary outcomes

  1. Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)

    Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.

    Time frame: Baseline and Week 6

  2. Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)

    A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.

    Time frame: Baseline and Week 6

  3. Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1

    A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with \<50% improvement from baseline in PGAP \[VAS\] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.

    Time frame: Week 6 and Week 10 to Week 12

07

Results

Posted May 21, 2015

Participant flow

Part 1
Participant flow — Part 1
MilestoneEtoricoxib 60 mgEtoricoxib 90 mgEtoricoxib 60 mg/Etoricoxib 60 mgEtoricoxib 60/Etoricoxib 90mgPlacebo
Started81846800118
Completed7194130096
Not completed99550022
Withdrew: Withdrawal by subject1110000
Withdrew: Technical problem50000
Withdrew: Protocol violation105000
Withdrew: Physician decision40000
Withdrew: Non-compliance with study drug11000
Withdrew: Lost to follow-up53001
Withdrew: Lack of efficacy37120017
Withdrew: Adverse event2624004
Part 2
Participant flow — Part 2
MilestoneEtoricoxib 60 mgEtoricoxib 90 mgEtoricoxib 60 mg/Etoricoxib 60 mgEtoricoxib 60/Etoricoxib 90mgPlacebo
Started003503630
Completed003343430
Not completed0016200
Withdrew: Adverse event00670
Withdrew: Withdrawal by subject00110
Withdrew: Protocol violation00100
Withdrew: Physician decision00120
Withdrew: Non-compliance with study drug00110
Withdrew: Lost to follow-up00120
Withdrew: Lack of efficacy00570

Outcome measures

PrimaryTime-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)

Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Scores on a scale
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)
Scores on a scaleEtoricoxib 60 mgEtoricoxib 90 mgPlacebo
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)-1.39 (-1.48 to -1.30)-1.37 (-1.48 to -1.26)-1.10 (-1.29 to -0.90)
Statistical analysis
  • Etoricoxib 60 mg vs Placebo · Tukey-Ciminera-Heysetrend test · p = 0.004 · Difference in least squares mean: -0.29 · 95% CI -0.49 to -0.09
  • Etoricoxib 90 mg vs Placebo · Tukey-Ciminera-Heysetrend test · p = 0.034 · Difference in least squares mean: -0.27 · 95% CI -0.48 to -0.06
PrimaryTime-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)

A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Scores on a scale
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)
Scores on a scaleEtoricoxib 60 mgEtoricoxib 90 mgPlacebo
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)-28.25 (-30.05 to -26.44)-30.96 (-33.13 to -28.79)-20.26 (-24.04 to -16.48)
Statistical analysis
  • Etoricoxib 60 mg vs Placebo · Tukey-Ciminera-Heyse trend test · p = <0.001 · Difference in least squares mean: -7.99 · 95% CI -11.85 to -4.13
  • Etoricoxib 90 mg vs Placebo · Tukey-Ciminera-Heyse trend test · p = <0.001 · Difference in least squares mean: -10.70 · 95% CI -14.74 to -6.66
SecondaryTime-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)

Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Scores on a scale
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)
Scores on a scaleEtoricoxib 60 mgEtoricoxib 90 mg
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)-1.39 (-1.48 to -1.30)-1.37 (-1.48 to -1.26)
Statistical analysis
  • Etoricoxib 60 mg vs Etoricoxib 90 mg · Tukey-Ciminera-Heysetrend test · p = 0.730 · Difference in least squares mean: 0.02 · 95% CI -0.10 to 0.14
SecondaryTime-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)

A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Scores on a scale
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)
Scores on a scaleEtoricoxib 60 mgEtoricoxib 90 mg
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)-28.25 (-30.05 to -26.44)-30.96 (-33.13 to -28.79)
Statistical analysis
  • Etoricoxib 60 mg vs Etoricoxib 90 mg · Tukey-Ciminera-Heyse trend test · p = 0.019 · Difference in least squares mean: -2.71 · 95% CI -4.98 to -0.45
SecondaryAverage Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1

A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with \<50% improvement from baseline in PGAP \[VAS\] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.

Time frame:
Week 6 and Week 10 to Week 12
Reported as:
Least squares mean · Scores on a scale
Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1
Scores on a scaleEtoricoxib 60 mg/Etoricoxib 60 mgEtoricoxib 60 mg/Etoricoxib 90 mg
Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1-11.96 (-14.96 to -8.97)-10.35 (-13.32 to -7.39)
Statistical analysis
  • Etoricoxib 60 mg/Etoricoxib 60 mg vs Etoricoxib 60 mg/Etoricoxib 90 mg · covariance model · p = 0.327 · Difference in the least squares mean: 1.61 · 80% CI -0.49 to 3.71
PrimaryPercentage of Participants Who Experienced at Least One Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

Time frame:
Up to 112 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced at Least One Adverse Event (AE)
Percentage of participantsEtoricoxib 60 mg - Part 1Etoricoxib 90 mg - Part 1Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2Placebo - Part 1
Percentage of Participants Who Experienced at Least One Adverse Event (AE)30.336.019.124.525.4
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

Time frame:
Up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an AE
Percentage of participantsEtoricoxib 60 mg - Part 1Etoricoxib 90 mg - Part 1Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2Placebo - Part 1
Percentage of Participants Who Discontinued Study Drug Due to an AE3.35.11.41.93.4

Adverse events

Collected over Up to 112 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib 60 mg - Part 1—7/819 (0.9%)25/819 (3.1%)
Etoricoxib 90 mg - Part 1—2/467 (0.4%)17/467 (3.6%)
Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2—4/350 (1.1%)6/350 (1.7%)
Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2—5/363 (1.4%)6/363 (1.7%)
Placebo - Part 1—0/118 (0%)6/118 (5.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventEtoricoxib 60 mg - Part 1Etoricoxib 90 mg - Part 1Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2Placebo - Part 1
Atrial fibrillationCardiac disorders0/8190/4671/3500/3630/118
Haemorrhoidal haemorrhageGastrointestinal disorders0/8190/4671/3500/3630/118
Non-cardiac chest painGeneral disorders2/8190/4671/3500/3630/118
ArthritisMusculoskeletal and connective tissue disorders0/8190/4671/3500/3630/118
Acute myocardial infarctionCardiac disorders0/8190/4670/3501/3630/118
Coronary artery diseaseCardiac disorders0/8190/4670/3501/3630/118
Gastroenteritis viralInfections and infestations0/8190/4670/3501/3630/118
PyomyositisInfections and infestations0/8190/4670/3501/3630/118
Hip fractureInjury, poisoning and procedural complications0/8190/4670/3501/3630/118
Cerebrovascular accidentNervous system disorders0/8190/4670/3501/3630/118
Most frequent other events
Most frequent other events
EventEtoricoxib 60 mg - Part 1Etoricoxib 90 mg - Part 1Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2Placebo - Part 1
HeadacheNervous system disorders25/81917/4676/3506/3636/118

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Etoricoxib 60 mgEtoricoxib 90 mgPlaceboTotal
Mean53.8 ± 11.954.0 ± 12.353.6 ± 11.053.8 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib 60 mgEtoricoxib 90 mgPlaceboTotal
Female6773951001172
Male1417318232
Disease Activity Score using C reactive protein (DAS28-CRP)
Disease Activity Score using C reactive protein (DAS28-CRP)(Scores on a scale)Etoricoxib 60 mgEtoricoxib 90 mgPlaceboTotal
Mean5.64 ± 0.995.62 ± 1.005.65 ± 1.125.63 ± 1.00
Patient Global Assessment of Pain
Patient Global Assessment of Pain(Scores on a scale)Etoricoxib 60 mgEtoricoxib 90 mgPlaceboTotal
Mean70.84 ± 15.5070.58 ± 15.0274.08 ± 14.2371.02 ± 15.24
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bickham K, Kivitz AJ, Mehta A, Frontera N, Shah S, Stryszak P, Popmihajlov Z, Peloso PM. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi: 10.1186/s12891-016-1170-0. PubMed 27502582 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jun 2014, 44 months.

Results were first posted in May 2015, 11 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 44 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2010
First posted
Sep 23, 2010
StartActual
Sep 27, 2010
Primary completionActual
Jun 9, 2014
CompletionActual
Jul 29, 2014
Results first posted
May 21, 2015
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01208181
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 23, 2010
Start date
Sep 27, 2010
Primary completion
Jun 9, 2014
Completion
Jul 29, 2014
Results posted
May 21, 2015
Last update
Jun 18, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion